Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRIG):

  • Bagust A, Boland A, Blundell M et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing therapy, March 2010

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Roche Products

II Professional/specialist and patient/carer groups:

  • Macmillan Cancer Support

  • Roy Castle Lung Cancer Foundation

  • British Thoracic Society

  • National Lung Cancer Forum for Nurses

  • Royal College of Nursing

  • Royal College of Physicians' Intercollegiate Lung Cancer Group

  • United Kingdom Oncology Nursing Society

III Other consultees:

  • NHS Cornwall and the Isles of Scilly

  • Department of Health

  • NHS Dudley

  • Welsh Assembly Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • NHS Quality Improvement Scotland

  • Eli Lilly and Company

  • British Thoracic Oncology Group

  • Liverpool Reviews and Implementation Group (LRIG)

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on erlotinib by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor David Ferry, Consultant Medical Oncologist, nominated by Eli Lilly and Company – clinical specialist

  • Dr Diane Parry, Consultant Physician and Lung Cancer Lead, nominated by Welsh Assembly Government – clinical specialist

  • Dr Yvonne Summers, Honorary Lecturer, nominated by Royal College of Physicians – clinical specialist

  • Dr Clive Mulatero, Senior Lecturer in Medical Oncology, nominated by Royal College of Physicians – clinical specialist

D The following individuals were nominated as NHS Commissioning experts by the selected PCT allocated to this appraisal. They gave their expert/NHS commissioning personal view on erlotinib by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Caroline Court, Consultant in Public Health Medicine and Public Health Lead for Cancer, NHS Cornwall, selected by NHS Cornwall and Isles Of Scilly – NHS Commissioning expert

E Representatives from the following manufacturer/sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products

  • National Institute for Health and Care Excellence (NICE)